Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA

2003 ◽  
Vol 188 (4) ◽  
pp. 916-926 ◽  
Author(s):  
Ellen E. Sheets ◽  
Robert G. Urban ◽  
Christopher P. Crum ◽  
Mary Lynne Hedley ◽  
Joseph A. Politch ◽  
...  
2006 ◽  
Vol 16 (3) ◽  
pp. 1032-1035
Author(s):  
S. N. Tabrizi ◽  
I. H. Frazer ◽  
S. M. Garland

This study evaluated the detection of human papillomavirus (HPV) 16 antibody in HPV 16–associated cervical intraepithelial neoplasia (CIN) in Australian women. Seroreactivity to HPV 16 L1 virus–like particles was assessed in patients with CIN 2 (n = 169) and CIN 3 (n = 229) lesions previously tested for the presence of HPV DNA. Seropositivity was significantly commoner in women with HPV 16 DNA–positive lesions (98/184) than in women with no HPV DNA in the lesion (15/47) or with HPV of types other than 16 in the lesion (43/167) (P = 0.0004). In addition, seropositivity was observed in 33% (55/169) of women with CIN 2 and 46% (106/229) of women with CIN 3, in keeping with the lower fraction of CIN 2 (57/169) than CIN 3 (127/229) biopsies positive for HPV 16 DNA. HPV 16 seropositivity is most common in women with HPV 16–associated CIN, but many patients with HPV-associated CIN 3 are seronegative, and HPV 16 seropositivity is common in women with CIN associated with other HPV types. Overall, HPV 16 serology is a poor predictor of presence of HPV 16–associated CIN 3 in patient population studied.


1999 ◽  
Vol 53 (2) ◽  
pp. 121-135 ◽  
Author(s):  
Elin M. Hennig ◽  
Zhenhe Suo ◽  
Steinar Thoresen ◽  
Ruth Holm ◽  
Stener Kvinnsland ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document